Future role of topical pimecrolimus in early stage mycosis fungoides?

Abstract

Effective therapeutic options are scarce for early stage mycosis fungoides. Guidelines recommend skin-directed therapies in the early stages of mycosis fungoides (stages IA–IIA). In Europe, skin-directed therapies for early stage mycosis fungoides were restricted to topical corticosteroids, phototherapy, or radiotherapy,1–3 until the European Commission approved chlormethine gel 160 μg/L for the topical treatment of mycosis fungoides type cutaneous T-cell lymphoma in adults in 2017.